ADPT Adaptive Biotechnologies Corp: Forward P/S Multiple
Adaptive Biotechnologies relies on high-precision automated immune mapping laboratories, as confirmed by the projected P/S metric on the current GURU.Markets platform chart, where the current figure is 16.00. The company strives for leadership in T-cell receptor sequencing to develop targeted therapies. Monitoring systems for minimal residual disease in oncology ensure stable growth, despite significant investments in research and development.
Financial and market metric breakdowns for Adaptive Biotechnologies Inc. (ADPT)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Debt to Equity Adaptive Biotechnologies|ADPT - Long-Term Liabilities to Equity|Short-Term Debt to Equity Ratio Adaptive Biotechnologies|ADPT - Company Cumulative Indebtedness|Debts to Book Capitalization Adaptive Biotechnologies Inc.|ADPT - Long-Term Debt Volume|Company Current Liabilities Adaptive Biotechnologies|Quick Ratio adaptivebiotech.com
- financial results and valuation multiples details:
ADPT - Company Net Income|Future Profit Adaptive Biotechnologies|ADPT - Company Value to Net Income|Forward P/E Multiple Adaptive Biotechnologies Corp|ADPT - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Adaptive Biotechnologies Inc.|ADPT - Operating income before deduction of amortization|Earnings per share for the last twelve months Adaptive Biotechnologies|ADPT - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months adaptivebiotech.com|ADPT - Net earnings per one share growth for the current year|Earnings growth forecast for next year Adaptive Biotechnologies
- sales and revenue indicators:
General company analysis:Adaptive Biotechnologies Corporation ADPT
The complexity of AI-driven immune mapping and patent protection drive the high business valuation of Adaptive Biotechnologies (ADPT). By analyzing the issuer's forward P/S ratio, investors compare market capitalization against expected revenue, which allows them to determine the premium paid for technological leadership or identify hidden valuation vulnerabilities amid stringent FDA regulation and reliance on biomedical grants.
Analysis of competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|PTGX: Forward P/S Multiple|Market Cap to Projected Revenue IMVT|KNSA (Kiniksa) - Forward P/S Multiple|Forward P/S Multiple Grifols SA|Price-to-Projected Revenue Ratio Celldex (CLDX)|AUPH: Future Price to Revenue|BioCryst - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio VERA (veratx.com)|Dianthus Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Pharvaris NV PHVS|ABCL (AbCellera Biologics Inc) - Forward Price-to-Revenue Multiple|TRML (Tourmaline) - Price-to-Projected Revenue Ratio|PGEN (Precigen, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio pharming.com PHAR|Forward Price-to-Revenue Multiple NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Forward Price to Sales|Forward P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Immunome Bio - Price-to-Projected Revenue Ratio|Gossamer Bio, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio kalvista.com KALV|Septerna (SEPN) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Pieris Pharma (PVLA)|Forward Price-to-Revenue Multiple SVRA|RIGL (Rigel Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple ANAB|ATXS - Market Cap to Future Revenue Ratio|Forward P/S Multiple ENGN (enGene)|RAPT - Forward Price-to-Revenue Multiple|Aerovate - Forward P/S Multiple|Forward Price to Sales ACRS (Aclaris Therapeutics, Inc)|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TLSA|Price-to-Projected Revenue Ratio Cabaletta Bio|Market Cap to Future Revenue Ratio Ventyx Biosciences Inc. VTYX|Price-to-Projected Revenue Ratio Theratechnologies Inc (THTX)|Price-to-Projected Revenue Ratio AVTX (Avalo Therapeutics Inc)|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|agenusbio.com (AGEN) - Market Cap to Future Revenue Ratio|Climb Bio - Forward P/S Multiple|Projected Price to Revenue Zura Bio Ltd (ZURA)|ATYR: Forward P/S Multiple|ADAG - Market Cap to Expected Sales Ratio|IMA (ImageneBio) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Shattuck Therapeutics STTK|Price-to-Projected Revenue Ratio Equillium, Inc. (EQ)|Market Cap to Expected Sales Ratio connectbiopharm.com|Forward P/S Multiple IMUX (Immunic)|Forward P/S Multiple Atara Biotherapeutics, Inc. ATRA|InflaRx GmbH - Forward P/S Multiple|XFOR (x4pharma.com) - Market Cap to Projected Revenue|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Future Price to Revenue CELU (Celularity)|Forward Price-to-Revenue Multiple INMB|BRNS (Barinthus Biotherapeutics Corp) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|SABS: Future Price to Revenue|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Forward Price to Sales ENLV|Q32 Bio Corp - Forward P/S Multiple|GOVX - Forward P/S Multiple|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|ibioinc.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Forward Price-to-Revenue Multiple XTL Biopharmaceuticals Ltd (XTLB)|Forward P/S Multiple BOLT|Forward P/S Multiple hcwbiologics.com (HCWB)|Aptevo Therapeutics Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales AIM|Aditxt Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Inc GRI|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Vyome Therapeutics|Price-to-Projected Revenue Ratio Revelation Biosciences|Forward Price-to-Revenue Multiple indaptusrx.com (INDP)|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|Forward P/S Multiple calcimedica.com (CALI)|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|ALLK: Market Cap to Projected Revenue|HOOKIPA - Forward P/S Multiple|Market Cap to Future Revenue Ratio IGM Biosciences, Inc.|ITOS: Forward P/S Multiple|Ocean Biomedical Inc (OCEA) - Forward P/S Multiple|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Market Cap to Projected Revenue THRD (Third Harmonic Bio Inc)
